HIV News and Research

RSS

Poxvirus' ability to hide from the immune system may aid vaccine design

The cowpox virus, a much milder cousin of the deadly smallpox virus, can keep infected host cells from warning the immune system that they have been compromised, researchers at Washington University School of Medicine in St. Louis have found.

16 Nov 2007

Petition aims to stem the flood of dangerous drugs reaching Americans

In a petition filed with the U.S. Food and Drug Administration, an international coalition of scientists and doctors seeks to compel the agency to stem the flood of dangerous drugs reaching American consumers by mandating the use of scientifically superior non-animal testing methods when those alternatives exist.

15 Nov 2007

Breakthrough innovation for high sensitivity TB and Malaria diagnostics

At this year's 39th World Forum for Medicine in Dusseldorf (MEDICA, November 14-17), Partec, a globally leading developer, manufacturer and provider of dedicated diagnostic solutions in the response to HIV/AIDS, Tuberculosis and Malaria is presenting a breakthrough innovation for high sensitivity TB and Malaria diagnostics in low- and middle-income countries.

15 Nov 2007

New explanation for how regulatory networks of genes evolved

When ancient retroviruses slipped bits of their DNA into the primate genome millions of years ago, they successfully preserved their own genetic legacy.

15 Nov 2007

EDMA calls for empowering people with diabetes

Type 2 diabetes and its complications are frequently diagnosed too late and the complications are often detected only at the time of diagnosis, concludes the European Parliament in its 2006 Written Declaration on Diabetes.

14 Nov 2007

STEP study of Merck's HIV vaccine to be unblinded

Merck & Co., Inc. and the HIV Vaccine Trials Network (HVTN) today announced that study volunteers in the STEP study of Merck's HIV vaccine (V520) will be told whether they received vaccine or placebo, and all study volunteers will be encouraged to continue to return to their study sites on a regular basis for ongoing risk reduction counseling and study-related tests.

14 Nov 2007

HIV drug resistance risk in mothers reduced by tenofovir/emtricitabine with nevirapine during labor

New research from the University of Alabama at Birmingham (UAB) shows that adding a single dose of two common anti-HIV drugs can prevent HIV-positive pregnant women from developing resistance to an entire class of drugs, potentially improving future treatment options.

14 Nov 2007

Hidden epidemic of sexually transmitted diseases in the U.S.

Health experts in the United States say the country has achieved an all-time record for a sexually transmitted disease.

14 Nov 2007

Volunteers in AIDS vaccine trial may be at greater risk of infection

Following the aborting of two international trials of an experimental AIDS vaccine, thousands of volunteers have been told the vaccine may have actually raised their risk of infection.

14 Nov 2007

Transplant organs infect patients with HIV and hep C

The cases of four transplant recipients in the U.S. who contracted HIV from a single high-risk organ donor is being investigated by the Centers for Disease Control (CDC).

13 Nov 2007

Brazilian experience of AIDS cocktails

AIDS continues to be a staggering global public health problem. The World Health Organization estimates that two million people in developing countries receive treatment known as HAART (highly active antiretroviral therapy), more commonly known as “AIDS cocktails.”

13 Nov 2007

New genetic lineage of Ebola virus discovered in great apes

The Zaire species of Ebolavirus (ZEBOV) remains the most virulent of the various known species. It alone is responsible for 88% of human deaths from haemorrhagic fever recorded since Ebola's discovery in 1976.

13 Nov 2007

FDA strengthens warnings for erythropoiesis-stimulating agents

The U.S. Food and Drug Administration has approved revised boxed warnings and other safety-related product labeling changes for erythropoiesis-stimulating agents (ESAs), which treat certain types of anemia.

13 Nov 2007

Early, routine testing for HIV is key to curbing the disease among teens

Half of all new HIV infections in the United States occur among 13 to 24 year olds, but adolescents rarely seek HIV testing. Now, new research from the Bradley Hasbro Children's Research Center suggests that early and widespread testing - both in schools and community centers - may be the key to effectively curbing the spread of HIV within this age group.

13 Nov 2007

Holiday sex common place in young Britons

Around one in five young Britons has sex with a new partner while overseas, finds research published ahead of print in the journal Sexually Transmitted Infections.

13 Nov 2007

Health officials to discuss links between commercial sex work, HIV transmission in Baltimore

Health officials from the Maryland Department of Health and Mental Hygiene and the Baltimore Health Department plan to hold the first in a series of meetings this month to discuss the links between commercial sex work and HIV transmission in an effort to curb the spread of the disease in the Baltimore area, the Baltimore Sun reports (Bor, Baltimore Sun, 11/9).

12 Nov 2007

Members of European Parliament launch Facebook campaign to reduce tax rate on condoms to curb HIV/AIDS in E.U.

Members of the European Parliament from the Socialist Group on Thursday in Brussels launched a campaign on the social networking Web site Facebook to cut tax rates on condoms in an effort to curb increasing HIV/AIDS rates in Europe, the Irish Examiner reports.

12 Nov 2007

Former Chair of Presidential Advisory Council on HIV/AIDS Hitt passes away

R. Scott Hitt -- a former HIV/AIDS physician and former chair of the Presidential Advisory Council on HIV/AIDS during the Clinton administration -- died Thursday of colon cancer at his home in West Hollywood, Calif., according to Hitt's friend and West Hollywood Mayor John Duran, the AP/San Francisco Chronicle reports.

12 Nov 2007

Seattle Post-Intelligencer examines reactions of people who participated in Merck's canceled HIV vaccine

The Seattle Post-Intelligencer on Friday examined the reaction of volunteers in the Seattle arm of Merck's recently halted HIV vaccine trial. According to the Post-Intelligencer, participants who were interviewed on the condition of anonymity have voiced "decidedly mixed feelings" about participating in the trial because of safety concerns (Paulson, Seattle Post-Intelligencer, 11/9).

12 Nov 2007